Edesa Biotech, Inc.
EDSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001540159
No open-market purchases or sales by Edesa Biotech, Inc. insiders were filed in the last 90 days; 33 institutions reported holding it in 13F filings for Q2 2026, worth $31.0M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +5 vs. previous quarter
- 33
- 13F valueReported value at the end of Q2 2026
- $31.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding EDSA, Q2 2026
No superinvestor reported holding EDSA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Edesa Biotech, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 (view filing) | Feb 26 | 13 daysLate | Brooks Michael JPresident | PPurchase | +2.00K | $1.57 | +$3.14K | +0.9%226.9K after | |
| Mar 10, 2026 (view filing) | Mar 10 | Same day | Nijhawan PardeepChief Executive Officer | PPurchase | +1.00K | $6.60 | +$6.60K | +0.2%628.8K after | |
| Mar 6, 2026 (view filing) | Mar 5 | 1 day | Nijhawan PardeepChief Executive Officer | PPurchase | +10.0K | $3.90 | +$39.0K | +2.5%402.7K after | |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Nijhawan PardeepChief Executive Officer | PPurchase | +10.0K | $4.26 | +$42.6K | +2.6%392.7K after | |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Nijhawan PardeepChief Executive Officer | PPurchase | +10.0K | $3.63 | +$36.3K | +2.7%382.7K after | |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Nijhawan PardeepChief Executive Officer | PPurchase | +2.00K | $2.00 | +$4.00K | +0.3%627.8K after | |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Nijhawan PardeepChief Executive Officer | PPurchase | +1.00K | $2.28 | +$2.28K | +0.3%372.7K after | |
| Mar 2, 2026 (view filing) | Feb 26 | 4 days | Nijhawan PardeepChief Executive Officer | PPurchase | +20.6K | $1.58 | +$32.5K | +3.5%615.8K after | |
| Mar 2, 2026 (view filing) | Feb 27 | 3 days | Nijhawan PardeepChief Executive Officer | PPurchase | +30.0K | $2.22 | +$66.6K | +8.8%371.7K after | |
| Mar 25, 2024 (view filing)7:00 PM ET | Mar 25 | Same day | Nijhawan Pardeep and 1 otherChief Executive Officer | PPurchase | +5.00K | $4.00 | +$20.0K | +1.5%341.7K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Edesa Biotech, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 827,500 | $6.73M | 4.12% | 00.0% | Unchanged |
| Rubric Capital Management LP | 669,500 | $5.44M | 0.05% | −18,000−2.6% | Reduced |
| Perceptive Advisors LLC | 563,239 | $4.58M | 0.07% | 00.0% | Unchanged |
| Millennium Management LLC | 561,751 | $4.57M | 0.00% | +561,751 | New |
| Stonepine Capital Management, LLC | 456,439 | $3.19M | 2.43% | +426,439+1,421.5% | Added |
| Boxer Capital Management, LLC | 205,000 | $1.67M | 0.13% | +205,000 | New |
| Banque Cantonale Vaudoise | 3 | $1.00M | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 81,839 | $665.4K | 0.00% | −4,127−4.8% | Reduced |
| Geode Capital Management, LLC | 80,879 | $657.6K | 0.00% | +3,825+5.0% | Added |
| Jane Street Group, LLC | 72,465 | $589.1K | 0.00% | −43,256−37.4% | Reduced |